Choose Your Country or Region

Levalbuterol tartrate

Name: Levalbuterol tartrate
Brand: Selleck Chemicals
SKU: S3153
Rating: 5 (1 reviews)

Synonyms: Levosalbutamol tartrate

Catalog No.S3153 Purity:99.69%

Levalbuterol HCl(Levosalbutamol tartrate) is a relatively selective beta2-adrenergic receptor agonist used for the treatment of asthma.

Levalbuterol tartrate Chemical Structure

CAS No. 661464-94-4

Purity & Quality Control

Batch: S315301 DMSO]100 mg/mL]false]Water]100 mg/mL]false]Ethanol]Insoluble]false Purity: 99.69%

99.69

Levalbuterol tartrate Related Products

Related Targets	α-adrenergic receptor β-adrenergic receptor Beta-Adrenergic Receptor	Click to Expand
Related Products	Zenidolol (ICI-118551) Hydrochloride Yohimbine HCl L755507 Atipamezole Higenamine hydrochloride Fenoterol hydrobromide Medetomidine HCl Rauwolscine hydrochloride Deoxycorticosterone acetate Detomidine HCl Naftopidil	Click to Expand
Related Compound Libraries	FDA-approved Drug Library Natural Product Library Neuronal Signaling Compound Library CNS-Penetrant Compound Library Anti-alzheimer Disease Compound Library	Click to Expand

Signaling Pathway

Adrenergic Receptor Signaling Pathway

Biological Activity

Description	Levalbuterol HCl(Levosalbutamol tartrate) is a relatively selective beta2-adrenergic receptor agonist used for the treatment of asthma.

In Vivo
In vivo	Racemic albuterol (7.5 mg, bid) results in a greater improvement in their forced expiratory volume in 1 second (FEV1) as well as in their asthma scores after 1 hour of continuous treatment compared to the Levalbuterol (3.75 mg, bid) administration in children with asthma. The greater improvement in asthma scores is maintained after the second hour of continuous therapy in the racemic albuterol group but not for forced expiratory volume in 1 second (FEV1) measurements. ^[1] Levalbuterol (1.25 mg) requires significantly fewer median total nebulizations and scheduled nebulizations compared with those in the racemic albuterol (2.5 mg) group in patients with asthma or chronic obstructive pulmonary disease (COPD). Disease symptom assessment and subject general well-being score scores improves significantly from baseline in both levalbuterol (1.25 mg) and racemic albuterol (2.5 mg) treatment groups, and beta-mediated adverse effects mean scores are significantly greater with levalbuterol versus racemic albuterol. ^[2]

References

Chemical Information & Solubility

Molecular Weight	628.71	Formula	C₃₀H₄₈N₂O₁₂
CAS No.	661464-94-4	SDF	Download Levalbuterol tartrate SDF
Smiles	CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O.C(C(C(=O)O)O)(C(=O)O)O
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 100 mg/mL ( (159.05 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 100 mg/mL

Ethanol : Insoluble

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):